In vitro anti-proliferative activities of the synthesized compounds against HCT-116 and MCF-7 cell lines their VEGFR-2 inhibitory activities on HCT-116 cell line and cytotoxicity for compound 11e against normal human lung cells (WI-38).

Comp. no.	In vitro cytotoxicity IC50a (μM)			VEGFR-2a (μM)
	HCT 116	MCF-7	WI-38
9a	30.15 ± 0.25	28.66 ± 0.2	NTb	NTb
9b	12.34 ± 0.09	15.26 ± 0.12	NTb	NTb
9c	20.62 ± 0.15	26.75 ± 0.24	NTb	NTb
9d	7.14 ± 0.025	9.85 ± 0.035	NTb	2.41 ± 0.16
11a	23.58 ± 0.18	32.16 ± 0.28	NTb	NTb
11b	10.7 ± 0.05	13.48 ± 0.1	NTb	1.55 ± 0.25
11c	10.45 ± 0.05	10.92 ± 0.05	NTb	1.38 ± 0.03
11d	13.78 ± 0.11	14.31 ± 0.15	NTb	2.32 ± 0.21
11e	1.14 ± 0.01	1.54 ± 0.01	63.41 ± 0.015	0.61 ± 0.01
12a	17.98 ± 0.15	25.18 ± 0.19	NTb	NTb
12b	8.65 ± 0.05	9.77 ± 0.06	NTb	0.53 ± 0.07
12c	9.25 ± 0.07	10.17 ± 0.05	NTb	0.74 ± 0.15
12d	7.15 ± 0.06	10.33 ± 0.05	NTb	1.61 ± 0.18
12e	19.44 ± 0.14	30.14 ± 0.26	NTb	NTb
12f	21.36 ± 0.15	26.11 ± 0.18	NTb	NTb
12g	16.39 ± 0.12	21.72 ± 0.15	NTb	NTb
Sorafenib	8.96 ± 0.05	11.83 ± 0.07	NTb	0.19 ± 0.15

^aData are presented as mean ± S. D of the IC₅₀ values from two different experiments.

^bNT: not tested.